Reading this on a mobile device? Try our optimized mobile version here:

February 5, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Alnylam licenses RNAi cholesterol drugs to Medicines Company
    Alnylam Pharmaceuticals granted the Medicines Company the right to develop and market a series of RNA interference-based, cholesterol-lowering drug candidates. The deal covers ALN-PCS02, an experimental intravenous RNAi treatment, and ALN-PCSsc, a preclinical injectable RNAi candidate. Alnylam will get $25 million immediately and as much as $180 million in potential milestone fees plus sales royalties. Genetic Engineering & Biotechnology News (2/4) LinkedInFacebookTwitterEmail this Story
Enterprise Integration
Harness the Full Value of an Enterprise Quality Management System by Integrating with Other Enterprise Applications to increase Organizational Efficiency and Effectiveness—Without Unnecessary Customizations. View Video Now.
  Health Care & Policy 
  • BioSante sells GVAX vaccines to Aduro BioTech
    Aduro BioTech agreed to pay $1 million upfront to purchase BioSante Pharmaceuticals' GVAX assets, including vaccines, cell lines and intellectual property. Aduro previously licensed the rights to the GVAX pancreas and prostate cancer vaccines. The new deal also covers vaccines for multiple myeloma, colon cancer and breast cancer. RTT News (2/4) LinkedInFacebookTwitterEmail this Story
  • Lab isolates precursors to lens cells
    Researchers at Monash University in Australia derived and purified lens epithelium, the tissue that serves as the base for the growth of the lens of the eye. The researchers said they were able to coax the precursor cells to turn into lens cells. The findings could speed the development of treatments for eye conditions by allowing testing on tissues in the lab. Yahoo/Asian News International (2/1) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Global Developments 
  • Zealand-Sanofi diabetes drug wins go-ahead in Europe
    Sanofi and Zealand Pharma obtained approval from the European Commision to market the drug Lyxumia, or lixisenatide, for treatment of diabetes. The prandial GLP-1 receptor agonist will be used with oral glucose-lowering treatments and/or basal insulin to control blood sugar levels. PharmaTimes (U.K.) (2/4) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • How "lend-lease" could accelerate Pentagon's biofuel push
    Creating a nationwide biomass lend-lease program could speed the development of drop-in biofuels for military use by lowering the cost of feedstocks, Jim Lane writes. Federal lands would be made available to advanced biofuel producers or feedstock suppliers in exchange for affordable drop-in biofuels for the military, Lane writes. (2/4) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Failure changes for the better, success for the worse."
--Seneca the Younger,
Roman philosopher, statesman and playwright

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information